emovis is now proudly part of FutureMeds, Europe’s 1st DCT Site Network. We have been a reliable, versatile service provider for phase Ib-IV clinical trials since 2001. As one of the best study sites in Germany, our teams have recruited more than 9,000 patients in over 250 studies across 120 indications and 14 therapeutic areas. emovis also successfully passed more than 30 audits in the last 5 years. Our Dedicated Research Site team consist of driven and experienced professionals. Whatever project you have in mind - true to our motto, “Nothing is impossible”- we are ready to take on the challenge. We strive to accelerate study timelines, streamline processes, lower costs, and improve data quality to help accelerate patient access to new treatments. In 2012, we launched the Homecare Visits (HCV) service, an innovative solution to improve the patient experience. Now present in 16 European countries and with over 1,100 dedicated homecare nurses in their database, Homecare Visits (HCV) is one of the cornerstones of FutureMeds’ DCT solution. Find out more: https://www.emovis.de/en/
